I continue my track record of poor entry levels. I was too greedy when I was trying to buy at $1.05 and missed out. I was too impatient when I bought at $1.70.
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game